May 23, 2018
Japan saw a string of new drug launches on May 22 as they joined the NHI price list the same day, including Chugai Pharmaceutical’s hemophilia A treatment Hemlibra (emicizumab) and a fixed-dose combo of the country’s first-in-class DPP-4 and SGLT2...read more